Fred D. Lublin

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Fred D. Lublin is an American neurologist and a renowned authority on the treatment of multiple sclerosis.[according to whom?] Along with colleagues at the National Multiple Sclerosis Society, his work claims to redefine the clinical course definitions of MS.[1]

Lublin is Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center in New York and Saunders Family Professor of Neurology at Mount Sinai School of Medicine. He sits on the Board of Directors at both the National Multiple Sclerosis Society and MS Hope for a Cure and has been listed in "Who's Who in Frontiers of Science and Technology" and New York Magazine's "Best Doctors" issue every year since 2000.[2][3][4]

According to his employer, in 2004, Lublin secured one of the largest grants ever given for MS research, a $25 million grant from the NIH, to study the benefits of combination drug therapy.[5] He is a consultant to the National Institutes of Health and to pharmaceutical/biotech companies in all phases of drug development in preparation for presentation to the FDA and their advisory panels.

He is the author of numerous scientific publications including Defining the Clinical Course of Multiple Sclerosis: Results of an International Survey (Neurology 46:907-911, 1996 PMID 8780061), one of the most frequently cited works in the field of multiple sclerosis.[6]


Lublin was born in 1946 in Philadelphia, Pa. He graduated from Temple University in 1968 and Jefferson Medical College in 1972. He completed his internship in internal medicine at the Bronx Municipal Hospital, Albert Einstein Medical Center and his residency at the New York Hospital, Cornell Medical Center.

He joined the staff at Mount Sinai Medical Center in April 2000.

Lublin was among the first in the United States to study Interferon β-1b and its ability to treat the relapsing-remitting form of multiple sclerosis; in 1993, IFN β-1b was approved by the U.S. Food and Drug Administration for that very purpose.[7]

He is the author of nineteen chapters, 136 publications and one text, and is a member of dozens of medical societies including: the National Multiple Sclerosis Society; the MSSM General Clinical Research Center Advisory Committee; and the Executive Committee of the International Medical & Scientific Board of the Multiple Sclerosis International Federation.


Partial list:

  • Combination Therapy in Multiple Sclerosis, 2003–2012, National Institutes of Health[8]
  • Double-Blind, Placebo-Controlled, 20-Week Parallel Group Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects with Multiple Sclerosis, 2002–Present, Acorda Therapeutics[9]
  • Randomized, Double-Blind, Placebo-Controlled Study to Compare the Effects of Different Dose Regimens of IGIV-Chromatography Treatment on Relapses in Patients with Multiple Sclerosis, 2002–Present, Bayer [10]
  • Study to Evaluate IV and Oral Steroids for MS Attacks, 2002–2005, National Multiple Sclerosis Society [8]
  • Study to Evaluate the Preliminary Efficacy, Pharmacokinetics and Immunogenicity of BMS-1 88667 Administered to Subjects with Relapsing-Remitting Multiple Sclerosis, 2001–2003, Bristol-Myers Squibb


Partial list:

  • Lublin, F.D., Whitaker, J.N., Eidelman, B.H., Miller, A.E., Arnason, B.G.W. and Burks, J.S. Management of Patients Receiving Interferon Beta-1b for Multiple Sclerosis: Report of a Consensus Conference. Neurology 46:12-18, 1996. PMID 8559358
  • Lublin, F.D. and Reingold, S.C. Defining the Clinical Course of Multiple Sclerosis: Results of an International Survey. Neurology 46:907-911, 1996. PMID 8780061
  • Lublin, F.D., Reingold, S.C. and the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Guidelines for Clinical Trials of New Therapeutic Agents in Multiple Sclerosis: Relations Between Study Investigators, Advisors and Sponsors. Neurology 48:572-574, 1997. PMID 9065528
  • Croul, S. Lublin, F.D., Del Valle, L., Oshinsky, R.J., Giordano, A., Khalili, K. & Ritchie, C.K. The Cellular Response of JC Virus T-Antigen-Induced Brain Tumor Implants to a Murine Intra-Ocular Model. Journal of Neuroimmunology 106:181-188, 2000. PMID 10814796
  • Kalman, B. and Lublin, F.D. Spectrum and classification of inflammatory demyelinating diseases of the central nervous system. Current Neurology and Neuroscience Reports, Demyelinating Disorders section 1:249-256, 2001. PMID 11898526
  • Lublin, F.D., Reingold, S.C. and The National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS. Placebo-Controlled Clinical Trials in Multiple Sclerosis: Ethical Considerations. Annals of Neurology 49:677-681, 2001. PMID 11357961
  • Tullman, M.J., Lublin, F.D. and Miller, A.E. Immunotherapy of Multiple Sclerosis- Current Practice and Future Directions. Journal of Rehabilitation Research and Development 39:273-286, 2002. PMID 12051470
  • Lublin, F.D. The Diagnosis of Multiple Sclerosis. Current Opinion in Neurology 15:253-256, 2002. PMID 12045721
  • Lublin, F.D. Modernize Your Approach to Multiple Sclerosis. Practical Neurology 1:44-49, 2002.
  • Lublin, F.D., Baier, M. and Cutter, G. Effect of Relapses on Development of Residual Deficit in Multiple Sclerosis. Neurology 61:1528, 2003. PMID 14663037
  • Lublin, F.D. History of Modern Multiple Sclerosis Therapy. Journal of Neurology 252 (Supple 3):3-9, 2005. PMID 16170498
  • Lublin, F.D. Multiple Sclerosis Trial Designs for the 21st Century: Building on Recent Lessons. Journal of Neurology 252 (Supple 5):46-53, 2005. PMID 16254702
  • Lublin, F.D. The Incomplete Nature of Multiple Sclerosis Relapse Reduction. Journal of Neurological Science 256: S14-18, 2007. PMID 17337274
  • DeAngelis T and Lublin F .D. Neurotherapeutics in Multiple Sclerosis: Novel Agents and Emerging Treatment Strategies. Mount Sinai Journal of Medicine 75:157-19-67, 2008. PMID 18500719
  • Fazekas, F., Lublin, F.D., Li, D., Freedman, M.S., Hartung, H.P., Rieckmann, P., Soelberg Sørensen, P., Maas-Enriquez, M., Sommerauer, B., Hanna, K. For the PRIVIG Study Group, the UBC MS/MRI Research Group. Intravenous Immunoglobulin in Relapsing-Remitting Multiple Sclerosis - A Dose-Finding Trial. Neurology 71:265-271, 2008. PMID 18645164


External links[edit]